Insider Selling: Heartflow (NASDAQ:HTFL) CEO Sells $194,500.00 in Stock

Key Points

• CEO insider sale: Heartflow CEO John Farquhar sold 3,890 shares at $50 each for $194,500 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 1.19% to 321,914 shares.
• Repeated selling activity: Farquhar has sold more than $7.9 million in Heartflow stock across several transactions since June, including a $1.63 million sale on September 10.
• Stock and outlook: HTFL traded near $49.54, close to its $51.78 one-year high. Analysts maintain a “Moderate Buy” consensus with an average $44.88 price target, while the company continues to report losses despite 47.7% year-over-year quarterly revenue growth.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John Farquhar sold 3,890 shares of the company's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $50.00, for a total transaction of $194,500.00. Following the sale, the chief executive officer owned 321,914 shares in the company, valued at $16,095,700. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Thursday, September 10th, John Farquhar sold 35,010 shares of Heartflow stock. The shares were sold at an average price of $46.42, for a total transaction of $1,625,164.20.
• On Friday, August 21st, John Farquhar sold 27,230 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total transaction of $1,361,500.00.
• On Tuesday, August 18th, John Farquhar sold 32,676 shares of Heartflow stock. The stock was sold at an average price of $45.00, for a total value of $1,470,420.00.
• On Friday, August 14th, John Farquhar sold 15,560 shares of Heartflow stock. The shares were sold at an average price of $39.06, for a total value of $607,773.60.
• On Monday, August 10th, John Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.31, for a total value of $638,730.22.
• On Friday, July 10th, John Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total value of $626,095.50.
• On Wednesday, June 24th, John Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00.

Heartflow Price Performance

Shares of HTFL traded down $0.34 during midday trading on Monday, hitting $49.54. 1,619,526 shares of the company traded hands, compared to its average volume of 1,556,569. Heartflow, Inc. has a one year low of $20.13 and a one year high of $51.78. The firm has a market cap of $4.31 billion and a P/E ratio of -27.07. The stock has a 50-day moving average of $35.52 and a 200-day moving average of $30.84.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. Sell-side analysts forecast that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HTFL shares. JPMorgan Chase & Co. upped their price target on shares of Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. Piper Sandler restated an "overweight" rating and set a $45.00 target price (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. Robert W. Baird set a $45.00 price target on Heartflow in a report on Friday, August 14th. UBS Group started coverage on Heartflow in a research report on Wednesday, September 9th. They set a "neutral" rating and a $55.00 price target for the company. Finally, Stifel Nicolaus boosted their price objective on Heartflow from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Heartflow has an average rating of "Moderate Buy" and an average target price of $44.88.

Institutional Trading of Heartflow

Hedge funds have recently made changes to their positions in the stock. TrueMark Investments LLC increased its stake in Heartflow by 1.4% in the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company's stock valued at $654,000 after acquiring an additional 379 shares during the last quarter. Strs Ohio boosted its holdings in shares of Heartflow by 35.3% in the 1st quarter. Strs Ohio now owns 4,600 shares of the company's stock worth $112,000 after purchasing an additional 1,200 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Heartflow in the 2nd quarter worth about $53,000. Mayport LLC increased its position in shares of Heartflow by 20.0% during the 2nd quarter. Mayport LLC now owns 12,000 shares of the company's stock valued at $352,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Essential Partners LLC purchased a new position in shares of Heartflow during the 1st quarter valued at about $57,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient's coronary arteries.

The company's primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.